MedWatch

Coloplast seeks more US catheter acquisitions: "We want increased coverage"

The US market plays a key role for all of Coloplast's business units, but the medical technology giant approaches the market in a different way and will only pursue acquisitions within two areas.

Coloplast CFOAnders Lonning-Skovgaard. | Photo: Niels Hougaard/ERH

Coloplast eyes enormous potential in the US market, where the company forecasts consolidated business growth in the double digits.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs